The dual challenges of limited therapeutic options due to de novo or acquired resistance and psychological distress in patients with melanoma necessitate innovative treatment strategies. Here, we identify paroxetine hydrochloride (PH), a Food and Drug Administration (FDA)-approved antidepressant, as an alternative therapeutic for BRAFV600E-mutated melanoma, including BRAFi/MEKi-resistant cases. Furthermore, our findings reveal that PH acts as an unrecognized inducer of pyroptosis. By triggering pyroptosis, PH remodels the tumor-permissive microenvironment in recurrent melanoma to potentiate anti-PD-1 therapy while maintaining a favorable safety profile. Mechanistically, PH impedes 5-hydroxytryptamine (5-HT) reuptake, leading to epigenetic reprogramming by reducing histone serotonylation (H3Q5ser) at the promoters of DNA repair genes. Impaired DNA damage repair pathways in turn trigger genome instability, proteostasis imbalance, and subsequent endoplasmic reticulum stress, ultimately inducing pyroptosis. Our findings uncover the underlying mechanism by which 5-HT drives melanoma progression and highlight PH as a promising candidate with multiple clinical potentials for treating melanoma.
Hepatocellular carcinoma (HCC) accounts for more than 90% of all liver cases and often responds poorly to conventional treatment modalities, including multi-kinase inhibitors and immune checkpoint inhibitors. Therefore, it is urgent to develop novel therapeutic options for HCC. In this study, we conducted high-throughput screening of histone demethylase inhibitors for HCC treatment. Among the inhibitors examined, Corin significantly suppressed the growth and proliferation of two HCC cell lines, HepG2 and Hep3B cells without affecting non-cancerous cells. Based on the targets of Corin, we identified HDAC1/KDM1A dual-positive HCC as a novel subtype of HCC. Transcriptome profiling indicated that this novel subtype possessed rapid proliferation and high DNA damage repair capacity. Additionally, Corin treatment upregulated FDX1 expression to trigger Cuproptosis, which suppressed HCC proliferation. Conclusively, Corin possesses potential application as a novel and effective therapeutic option for HCC that simultaneously inhibits KDM1A and HDAC1 expression.
The lack of a favorable tumor immune microenvironment (TIME) results in limited response rates to immune checkpoint blockade (ICB) across human solid tumors, necessitating the development of novel combination strategies. In this study, we repurposed FK228, an US FDA-approved histone deacetylase inhibitor that is used clinically in non-solid tumor treatment, as a novel ICB sensitizer in solid tumors and revealed the diverse regulatory functions of FK228 in the TIME. FK228 serves as a novel necroptosis inducer in cancer cells by triggering endoplasmic reticulum stress. This in turn enhances the immunogenicity of cancer cells and increases the infiltration of tumor-killing immunocytes, including CD8+ T and natural killer cells, particularly activating tumor-infiltrated CD8+ T cells. Meanwhile, FK228 treatment shifts macrophages toward the pro-inflammatory phenotype. Moreover, the combined use of FK228 and a PD-L1 inhibitor significantly delay tumor growth and extend the survival of tumor bearing mice. Overall, our findings reveal new possibilities for the clinical application of FK228 in solid tumors and underscore the critical role of histone deacetylases in maintaining the immune-unfavorable TIME.
1 January 2026 in Ferroptosis and Oxidative Stress
Ferroptosis is an iron-dependent form of regulated cell death that has attracted considerable attention as a promising therapeutic strategy because of its ability to eliminate tumor cells. However, tumors are multicellular ecosystems in which malignant cells coexist with diverse stromal and immune cell populations that critically shape tumor progression, anti-tumor immunity, and therapeutic responses. Emerging evidence indicates that ferroptosis exerts fundamentally distinct biological effects across these non-malignant cell populations, extending far beyond direct tumor cell killing. In this review, we propose a cell type-centered conceptual framework in which the consequences of ferroptosis are determined primarily by cellular context rather than by ferroptosis itself. While ferroptosis resistance enables certain cell types, such as fibroblasts and macrophages, within the tumor microenvironment (TME) to maintain tumor-promoting functions, ferroptosis compromises the persistence and effector activity of cytotoxic lymphocytes, including CD8+ T cells and natural killer cells. Conversely, ferroptosis in neutrophils and polymorphonuclear myeloid-derived suppressor cells may generate oxidized lipid mediators that paradoxically reinforce immune suppression despite reducing cell abundance. Therefore, in this review, we integrate recent advances in understanding ferroptosis across major nonmalignant cell populations within the TME, focusing on its effects on cell fate, functional plasticity, and anti-tumor immunity. We further discuss how these insights may guide the development of precision ferroptosis-based therapies that selectively target tumor-promoting cell states while preserving protective immune responses.